{"analyses":[{"ciLowerLimit":"0.08","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.43","groupDescription":"Gray's test was stratified by randomization stratification factors.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.00002","paramType":"Hazard Ratio (HR)","paramValue":"0.19","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"23.1","value":"12.6"},{"groupId":"OG001","lowerLimit":"31.3","upperLimit":"56.1","value":"44.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"description":"Event rate estimated at 12 months for time from alloHCT to first onset of moderate or severe cGVHD defined by NIH consensus criteria within 2 years after day 0. Death within 2 years after day 0 without prior moderate or severe cGVHD was considered a competing event. cGVHD was assessed and graded by an independent EAC.\n\nEach participant in the study is followed for up to 730 days after transplant. The primary analysis was triggered by the 56th cGFS event (ie, when 56 participants had died or had moderate or severe chronic GVHD) and was not based on the duration of follow-up. Therefore, the analysis was conducted using all available data at the time that the 56th cGFS event occurred, and the event rate of moderate or severe cGVHD at 12 months was estimated regardless of the length of follow-up for individual participants. At the time of analysis, not all participants have reached 730 days of follow-up because they enrolled at different times.","dispersionType":"95% Confidence Interval","groups":[{"description":"Orca-T administered after myeloablative conditioning followed by single-agent tacrolimus","id":"OG000","title":"Orca-T"},{"description":"Unmanipulated allograft from peripheral blood of a matched donor after myeloablative conditioning followed by tacrolimus and methotrexate","id":"OG001","title":"Standard of Care"}],"paramType":"NUMBER","populationDescription":"ITT","reportingStatus":"POSTED","timeFrame":"Day 0 through 730 days after transplantation","title":"Event Rate at 12 Months for Time to Moderate or Severe cGVHD Per EAC","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}